



Dynavax Technologies Corporation  
Investor Relations Department  
2929 Seventh Street  
Berkeley, CA 94710  
United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

**NASDAQ: DVAX**

Last Trade: 18.75

Trade Time: 4:00 PM ET  
Dec 14, 2017

Change: -0.25 (-1.316%)

Day Range: 18.48 - 19.50

52-Week Range: 3.70 - 24.45

Volume: 949,044

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Dec 5, 2017

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Nov 27, 2017

[Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

Nov 9, 2017

[Dynavax Announces FDA Approval of HEPLISAV-B\(TM\) for Prevention of Hepatitis B in Adults](#)

Nov 3, 2017

[Dynavax Reports Third Quarter 2017 Financial Results](#)

Oct 19, 2017

[Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Jul 10, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)